Contraceptive and noncontraceptive advantages of dienogest and ethinylestradiol contraceptive pills – a case report Case report
Article Sidebar
Published:
Jun 30, 2016
Keywords:
dienogest, dysmenorrhea, acne, fertility
Main Article Content
Abstract
Recent contraception researches focus on providing both contraceptive properties and noncontraceptive health and lifestyle advantages. Ethinylestradiol + dienogest (EE + DNG) improve heavy menstrual bleeding, cycle regularity, dysmenorrhea and acne. According to many recent researches EE + DNG contraception is well tolerated and safe.
Article Details
How to Cite
Łukasiewicz , M. (2016). Contraceptive and noncontraceptive advantages of dienogest and ethinylestradiol contraceptive pills – a case report. Medycyna Faktow (J EBM), 9(2(31), 166-170. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2256
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Oddens B.J.: Women’s satisfaction with birth control: a population survey of physical and psychological effects of oral contraceptives, intrauterine devices, condoms, natural family planning, and sterilization among 1466 women. Contraception 1999; 59(6): 357-362.
2. Pérez-Campos E.F.: Ethinylestradiol/dienogest in oral contraception. Drugs 2010; 70(6): 681-689.
3. Ruan X., Seeger H., Mueck A.O.: The pharmacology of dienogest. Maturitas 2012; 71(4): 337-344.
4. Foster R.H., Wilde M.I.: Dienogest. Drugs 199; 56(5): 825-833; discussion 834-835.
5. Raudrant D., Rabe T.: Progestogens with antiandrogenic properties. Drugs 2003; 63(5): 463-492.
6. Davis S.R., Bitzer J., Giraldi A. et al.: Change to either a nonandrogenic or androgenic progestin-containing oral contraceptive preparation is associated with improved sexual function in women with oral contraceptive-associated sexual dysfunction. J. Sex. Med. 2013; 10(12): 3069-3079.
7. Krowchuk D.P., Stancin T., Keskinen R. et al.: The psychosocial effects of acne on adolescents. Pediatr. Dermatol. 1991; 8(4): 332-338.
8. Palombo-Kinne E., Schellschmidt I., Schumacher U., Gräser T.: Efficacy of a combined oral contraceptive containing 0.030 mg ethinylestradiol/ 2 mg dienogest for the treatment of papulopustular acne in comparison with placebo and 0.035 mg ethinylestradiol/2 mg cyproterone acetate. Contraception 2009; 79(4): 282-289.
9. Golbs S., Domhardt R., Radowicky S. et al.: Clinical findings with the oral contraceptive combination ethinylestradiol/dienogest in Poland. Methods Find. Exp. Clin. Pharmacol. 2002; 24(9): 585-592.
10. Golbs S., Domhardt R., Presl J. et al.: Clinical findings with the oral contraceptive combination ethinylestradiol/dienogest in the Czech Republic. Methods Find. Exp. Clin. Pharmacol. 2002; 24(10): 689-696.
11. Wiegratz I., Mittmann K., Dietrich H. et al.: Fertility after discontinuation of treatment with an oral contraceptive containing 30 microg of ethinyl estradiol and 2 mg of dienogest. Fertil. Steril. 2006; 85(6): 1812-1819.
12. Wiegratz I., Stahlberg S., Manthey T. et al.: Effect of extended-cycle regimen with an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on bleeding patterns, safety, acceptance and contraceptive efficacy. Contraception 2011; 84(2): 133-143.
13. Wiegratz I., Stahlberg S., Manthey T. et al.: Effects of conventional or extended-cycle regimen of an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on various hemostasis parameters. Contraception 2008; 78(5): 384-391.
14. Dinger J., Assmann A., Möhner S., Minh T.D.: Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study. J. Fam. Plann. Reprod. Health Care 2010; 36(3): 123-129.
2. Pérez-Campos E.F.: Ethinylestradiol/dienogest in oral contraception. Drugs 2010; 70(6): 681-689.
3. Ruan X., Seeger H., Mueck A.O.: The pharmacology of dienogest. Maturitas 2012; 71(4): 337-344.
4. Foster R.H., Wilde M.I.: Dienogest. Drugs 199; 56(5): 825-833; discussion 834-835.
5. Raudrant D., Rabe T.: Progestogens with antiandrogenic properties. Drugs 2003; 63(5): 463-492.
6. Davis S.R., Bitzer J., Giraldi A. et al.: Change to either a nonandrogenic or androgenic progestin-containing oral contraceptive preparation is associated with improved sexual function in women with oral contraceptive-associated sexual dysfunction. J. Sex. Med. 2013; 10(12): 3069-3079.
7. Krowchuk D.P., Stancin T., Keskinen R. et al.: The psychosocial effects of acne on adolescents. Pediatr. Dermatol. 1991; 8(4): 332-338.
8. Palombo-Kinne E., Schellschmidt I., Schumacher U., Gräser T.: Efficacy of a combined oral contraceptive containing 0.030 mg ethinylestradiol/ 2 mg dienogest for the treatment of papulopustular acne in comparison with placebo and 0.035 mg ethinylestradiol/2 mg cyproterone acetate. Contraception 2009; 79(4): 282-289.
9. Golbs S., Domhardt R., Radowicky S. et al.: Clinical findings with the oral contraceptive combination ethinylestradiol/dienogest in Poland. Methods Find. Exp. Clin. Pharmacol. 2002; 24(9): 585-592.
10. Golbs S., Domhardt R., Presl J. et al.: Clinical findings with the oral contraceptive combination ethinylestradiol/dienogest in the Czech Republic. Methods Find. Exp. Clin. Pharmacol. 2002; 24(10): 689-696.
11. Wiegratz I., Mittmann K., Dietrich H. et al.: Fertility after discontinuation of treatment with an oral contraceptive containing 30 microg of ethinyl estradiol and 2 mg of dienogest. Fertil. Steril. 2006; 85(6): 1812-1819.
12. Wiegratz I., Stahlberg S., Manthey T. et al.: Effect of extended-cycle regimen with an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on bleeding patterns, safety, acceptance and contraceptive efficacy. Contraception 2011; 84(2): 133-143.
13. Wiegratz I., Stahlberg S., Manthey T. et al.: Effects of conventional or extended-cycle regimen of an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on various hemostasis parameters. Contraception 2008; 78(5): 384-391.
14. Dinger J., Assmann A., Möhner S., Minh T.D.: Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study. J. Fam. Plann. Reprod. Health Care 2010; 36(3): 123-129.